The expansions will add peptide manufacturing capacity.
CordenPharma announced on May 13, 2021 that it plans to expand its non-GMP capacity at its Centre of Excellence for Peptide Process Development in Frankfurt, Germany, and increase its upstream capacity at its CordenPharma Colorado site with the introduction of a new 3000-L solid phase peptide synthesis (SPPS) vessel.
The capacity expansions fall in line with CordenPharma’s strategy to provide its customers with quick and economically appealing solutions, the company said in a press release. In addition to the new SPPS vessel, CordenPharma plans to add a second 100-cm high-pressure chromatography column at its CordenPharma Colorado site.
“This additional column will provide the capacity to purify several tons of peptide annually, which in conjunction with our existing 100 and 80-cm columns, gives us more flexibility and redundancy to maximize supply security for all of our partners,” said Matthieu Giraud, PhD, global director of the Peptides, Lipids & Carbohydrates Platform, CordenPharma, in the press release.
Source: CordenPharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.